Sanofi (SNY) Capital Expenditures (2009 - 2025)

Sanofi has disclosed Capital Expenditures across 9 years of filings, most recently posting -$4.1 billion for Q4 2025.

• In Q4 2025, Capital Expenditures fell 20.63% year-over-year to -$4.1 billion; the TTM figure through Dec 2025 stood at -$12.9 billion (down 16.01% YoY), while the FY2025 annual figure was $4.1 billion, up 19.09% from the prior year.
• Capital Expenditures came in at -$4.1 billion for Q4 2025 at Sanofi, down from -$3.4 billion in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of -$2.2 billion in Q4 2022 to a low of -$4.1 billion in Q4 2025.
• Average Capital Expenditures over 5 years is -$3.0 billion, with a median of -$3.1 billion recorded in 2023.
• Year-over-year, Capital Expenditures increased 5.9% in 2021 and plunged 39.24% in 2023.
• Over 5 years, Capital Expenditures stood at -$2.3 billion in 2021, then advanced by 3.92% to -$2.2 billion in 2022, then sank by 39.24% to -$3.1 billion in 2023, then fell by 9.19% to -$3.4 billion in 2024, then dropped by 20.63% to -$4.1 billion in 2025.
• Per Business Quant data, the three most recent Capital Expenditures figures were -$4.1 billion in Q4 2025, -$3.4 billion in Q4 2024, and -$3.1 billion in Q4 2023.